• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

I'm Not Bailing on Johnson & Johnson Now

Don't forget, this is a very large company with a lot more than the vaccine going on.
By STEPHEN GUILFOYLE
Apr 13, 2021 | 10:47 AM EDT
Stocks quotes in this article: JNJ, PFE, BNTX, MRNA, AZN, NVAX

Warning !! I guess we should have seen this coming. Last Wednesday, a mass vaccination site in Colorado was closed after several people reported side effects after receiving the viral-vector based COVID-19 vaccine developed by Johnson & Johnson (JNJ) . At that point, 4.5 million doses of this vaccine had gone into American arms and of those, 129 individuals had experienced side effects serious enough to go to an Emergency Room.

Then last Friday, the European Medicines Agency, or EMA, initiated a review of the possibility of a linkage between this COVID-19 vaccine developed by Johnson & Johnson and blood clots after four serious cases of "unusual" clots accompanied by low counts of blood platelets on the continent had occurred following vaccination. The JNJ "one and done" jab had been approved for emergency use in Europe, but had not yet been rolled out.

Bang !!

The news broke. I had already submitted Market Recon (here) to the editorial staff. This news surely would have changed my morning column. In the U.S., the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) jointly recommended a pause in the public use of JNJ's COVID-19 vaccine in order to investigate these rare but severe cases of unusual blood clotting after six U.S. recipients had developed this disorder within two weeks of inoculation. According to the New York Times, all six cases involve females, with one already having passed away and another currently in critical condition.

Patients who have already received the JNJ jab are being advised by both of these U.S. regulatory agencies to notify their doctors if they should develop headache, abdominal pain, leg pain, or shortness of breath within three weeks of said jab. Doctors are being cautioned that they should not follow the normal course of treating blood clots, that would be to use a drug known as heparin, as with this rare type of clotting with low counts of platelets, heparin could be dangerous.

Oddly enough, at least so far, the two vaccines based on experimental messenger RNA technology, the offerings from Pfizer (PFE) / BioNTech (BNTX) and Moderna (MRNA) have to this point, appeared to be both safe and effective. Of course we don't know what long-term effects any of these vaccines might ultimately show. The viral vector based technology based vaccines developed by Johnson & Johnson as well as AstraZeneca (AZN) , which is a more tried and true method of vaccine creation, have had more questions raised around side effects and more specifically blood clotting. Several European nations have paused and restarted usage of the AstraZeneca shot which is yet to gain emergency use authorization in the U.S.

Impact?

Does this slow down the effort to broaden the vaccination effort in the U.S.? Of course, but perhaps not to the extent that it might have had the JNJ shot been the game changer that we had originally thought it might be. They have had issues with the manufacturing process, and quite frankly have not brought to bear the numbers of shots that we had thought they might early on. Pfizer/BioNTech and Moderna have really stepped up to the plate in a time of crisis. This morning, the stocks of all three of these vaccine makers as well as that of Novavax (NVAX) whose vaccine candidates could apply for emergency use authorization as soon as May are all trading higher as JNJ's stock shares sold off a bit, currently down about 2%.

What would be a nightmare for not only the reopening of the economy, or simply a return to normal life, would be a problem with either of the two vaccines currently in widespread use in the U.S. For now, it is key to note that JNJ's EMU has not been revoked, not has there has been any causation established between this vaccine and those patients. These events remain extremely rare and need to be looked into.

My Thoughts

I am long JNJ, MRNA and PFE. Am I bailing out of JNJ right now? No. That said, sans any news events, I would look for this morning's gap to fill at some point. In the meantime, the shares remain well entrenched within the confines of a consolidating base in place since January. I don't love the stock. I have held it a long time and I am only up small, though the stock does yield 2.55%.

There is really no reason in my opinion to act unless the 200 day SMA fails to hold, all the way down at $151. Regulators may very well decide that the benefits still outweigh the risks and then inoculation goes on, with an extra warning. Don't forget, this is a very large company with a lot more than this going on. If you like JNJ, this does not change your mind. If you had a JNJ jab scheduled for next week, which one of my children had, then you may want to change that appointment, rather than wait for an update on the JNJ shot from regulators.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long JNJ, PFE, MRNA equity.

TAGS: Investing | Markets | Stocks | Technical Analysis | Trading | Healthcare | Coronavirus

More from Investing

Stop Wishing, Hoping and Praying and Take Control of Your Investing

James "Rev Shark" DePorre
Jul 2, 2022 10:00 AM EDT

The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.

If You've Got Time, These Three Dividend Aristocrats Should Pay Off

Bob Ciura
Jul 2, 2022 7:30 AM EDT

There high-growth dividend stocks will be here over the long haul.

Welcome to Second Semester on Wall Street, Here's How to Make the Grade

Jim Collins
Jul 1, 2022 4:36 PM EDT

Think you can own big tech? You might just get an 'F' for that. Here's what will get you on the other side of this year.

We Got a Break, but the Heat Is Still On

James "Rev Shark" DePorre
Jul 1, 2022 4:22 PM EDT

A limited rally cooled some of the negativity on the market, but guess what's going to hit the fan soon?

Coupang Could Make a Bigger Trading Bounce

Bruce Kamich
Jul 1, 2022 1:56 PM EDT

Here's where nimble traders could probe the long side.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • 04:41 PM EDT PAUL PRICE

    First-Half Results - Putrid; Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 mark...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login